Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA ® (finerenone), which ...

Because your kidneys are so essential for your well-being, keeping them healthy and functioning at their best is ...

Dietitians can help to ensure that nutrition care for heart health in chronic kidney disease (CKD) is comprehensive, personalized, and realistic.

In the FINE-ONE trial, finerenone met its primary endpoint by significantly reducing the urinary albumin-to-creatinine ratio by 25% compared with placebo over 6 months in adults with T1D and CKD. The ...

Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.

In patients with T2D and CKD, finerenone lowers the risk for adverse cardiovascular and kidney events compared with placebo, regardless of how many treatment goals they have achieved.

Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...

Discover the rising prevalence of chronic kidney disease in Singapore and the nation's efforts to manage this growing health ...